NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01719536,Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients,https://clinicaltrials.gov/study/NCT01719536,Convince,COMPLETED,The purpose of this study is to compare icotinib with induction and maintenance chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation.,NO,NSCLC,DRUG: Icotinib|DRUG: Chemotherapy,"Progression Free Survival, A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed., 12 months","Overall survival, Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive., 20 months|Objective response rate, Number of participants who achieve complete response or partial response. Either complete response (CR) or partial response (PR) will be evaluated by RECIST, confirmed at least 28 days following the date of the initial response., 12 weeks",,"Betta Pharmaceuticals Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,296,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BD-IC-IV36,2012-12,2016-09,2017-02-07,2012-11-01,,2019-07-05,"The First Affiliated Hospital of Anhui Medical Univercity, Hefei, Anhui, 230022, China|Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, 100853, China|Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing, Beijing, 101149, China|Xinqiao Hospital, The Third Military Medical University, Chongqing, Chongqing, 400037, China|The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, 510120, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China|Hebei Provincal Tumor Hospital, Shijiazhuang, Hebei, 050011, China|Harbin Medical Univercity Cancer Hospital, Harbin, Heilongjiang, 110001, China|Henan Provincal Tumor Hospital, Zhengzhou, Henan, 450003, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210009, China|Jiangsu Provincal Tumor Hospital, Nanjing, Jiangsu, 210029, China|The First Bethune Hospital of Jilin Univercity, Changchun, Jilin, 130021, China|The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China|Shandong Cancer Hospital, Jinan, Shandong, 250117, China|Shanghai Chest Hospital Affiliated to Shanghai Jiaotong Univercity, Shanghai, Shanghai, 200030, China|Zhongshan Hospital Affiliated to Fudan Univercity, Shanghai, Shanghai, 200032, China|Changhai Hospital, The Second Military Medical University, Shanghai, Shanghai, 200433, China|Xijing Hospital, Xian, Shanxi, 710032, China|Sichuan Provincal Tumor Hospital, Chengdu, Sichuan, 610041, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China",
